In a letter addressed to Vertex CEO Reshma Kewalramani, Vertex Save United States wrote that Vertex needs to offer its cystic fibrosis drugs at economical costs, use them on thoughtful usage basis and problem licenses to generic drugmakers in countries where the drugmaker does not plan to supply the drug in the near future..
” Some of us are lucky enough to be seeing the fantastic benefits to health from Vertex … drugs. Others are not and are desperate for gain access to, literally dying waiting,” the group stated in the letter.
” We received the letter and will be replying straight. We believe its suitable for us to respond to them straight initially versus through journalism,” the representative stated..
Check out the full post here.
Maia Anderson –
Tuesday, October 27th, 2020
Trikafta is a triple combination treatment that is reliable in about 90 percent of cystic fibrosis clients, according to STAT..
Vertex Save United States accused the drugmaker of stopping working to follow human rights guidelines for drugmakers issued by the United Nations to make sure fair access to drugs, STAT reported..
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.
An advocacy group called Vertex Save Us is urging Vertex Pharmaceuticals to take steps to resolve the “fatal inequality” in access to its cystic fibrosis drug, Trikafta, STAT reported..
More short articles on pharmacy: FDA is letting COVID-19 vaccine makers skip examination before emergency authorizationSenators call for hearing on defense departments function in Operation Warp SpeedFloridas strategy to import less expensive drugs from Canada strikes problem.
A Vertex representative told STAT the drugmaker “supports the principles developed under the United Nations Universal Declaration of Human Rights which addresses equality of all humans.”.
The spokesperson said Vertex currently has a caring usage program for Trikafta, though Vertexs site states the program will only be offered in nations where Vertex intends to file for regulatory approval of the drug. The drugmaker declined to say where the drug would be registered, STAT reported..